Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion. Through ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Take Eli Lilly (NYSE: LLY), a pharmaceutical giant that has been performing well in recent years. The drugmaker is not resting on its laurels. Lilly has been signing deals and loo ...

INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion. SiteOne, founded in 2010, is ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...